Bayer Return on Investment 2010-2024 | BAYRY

Current and historical return on investment (ROI) values for Bayer (BAYRY) over the last 10 years.
Bayer ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2024-06-30 $0.84B $78.88B 1.08%
2024-03-31 $0.83B $80.07B 1.06%
2023-12-31 $0.66B $77.12B 0.85%
2023-09-30 $-0.49B $74.73B -0.63%
2023-06-30 $4.63B $80.34B 5.82%
2023-03-31 $5.85B $80.06B 7.33%
2022-12-31 $7.39B $76.62B 9.16%
2022-09-30 $8.49B $81.51B 10.34%
2022-06-30 $7.91B $81.16B 9.66%
2022-03-31 $4.98B $83.33B 6.08%
2021-12-31 $3.97B $82.40B 4.79%
2021-09-30 $3.23B $80.48B 4.01%
2021-06-30 $-8.38B $81.02B -10.49%
2021-03-31 $-17.51B $87.64B -22.20%
2020-12-31 $-18.47B $72.99B -22.93%
2020-09-30 $-20.02B $77.93B -23.29%
2020-06-30 $-7.68B $76.87B -8.55%
2020-03-31 $5.23B $94.43B 5.60%
2019-12-31 $4.69B $94.56B 4.97%
2019-09-30 $-0.36B $93.31B -0.38%
2019-06-30 $3.43B $91.80B 3.48%
2019-03-31 $4.00B $97.72B 3.91%
2018-12-31 $4.62B $99.04B 4.94%
2018-09-30 $9.80B $105.54B 11.85%
2018-06-30 $6.28B $107.11B 9.18%
2018-03-31 $7.04B $62.27B 12.73%
2017-12-31 $6.67B $55.77B 13.11%
2017-09-30 $7.27B $48.54B 14.46%
2017-06-30 $7.64B $54.61B 15.39%
2017-03-31 $7.69B $44.64B 16.21%
2016-12-31 $7.79B $53.20B 16.29%
2016-09-30 $7.91B $46.09B 17.13%
2016-06-30 $7.65B $45.78B 16.78%
2016-03-31 $7.26B $46.22B 16.10%
2015-12-31 $6.94B $46.59B 15.60%
2015-09-30 $6.62B $43.75B 14.50%
2015-06-30 $6.71B $43.81B 14.82%
2015-03-31 $6.70B $43.78B 15.31%
2014-12-31 $7.32B $51.45B 17.09%
2014-09-30 $7.64B $42.05B 19.72%
2014-06-30 $7.43B $37.79B 20.18%
2014-03-31 $7.09B $40.01B 19.63%
2013-12-31 $6.55B $35.06B 18.78%
2013-09-30 $6.57B $34.37B 19.13%
2013-06-30 $6.00B $35.00B 17.75%
2013-03-31 $5.29B $35.16B 15.83%
2012-12-31 $5.09B $32.84B 15.08%
2012-09-30 $4.54B $32.32B 12.98%
2012-06-30 $4.92B $33.25B 13.55%
2012-03-31 $5.46B $36.70B 14.61%
2011-12-31 $4.53B $37.55B 11.87%
2011-09-30 $3.84B $37.56B 10.01%
2011-06-30 $2.83B $37.66B 7.40%
2011-03-31 $2.39B $39.91B 6.21%
2010-12-31 $2.22B $38.30B 5.71%
2010-09-30 $2.46B $37.12B 6.15%
2010-06-30 $3.24B $38.34B 7.82%
2010-03-31 $3.00B $41.98B 7.13%
2009-12-31 $3.04B $42.41B 7.35%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $719.145B 74.49
Novo Nordisk (NVO) Denmark $464.190B 33.48
Johnson & Johnson (JNJ) United States $345.687B 14.02
AbbVie (ABBV) United States $303.100B 15.95
Merck (MRK) United States $251.749B 16.73
AstraZeneca (AZN) United Kingdom $199.805B 17.00
Novartis AG (NVS) Switzerland $197.798B 13.15
Pfizer (PFE) United States $146.038B 9.99
Sanofi (SNY) $120.547B 10.92
Innoviva (INVA) United States $1.122B 9.34